Drug intelligence / Profile preview

ST8161AA1

Development stage: Unknown
Lead developer: Alfasigma
Modality: Small Molecules
Administration: Local (intratumoral Or Topical, As Studied With AvidinOX Anchoring)

Overview

ST8161AA1 is a novel **biotinylated gimatecan-derived camptothecin** designed to be used in conjunction with the AvidinOX delivery platform for topical or localized cancer therapy. It demonstrates anticancer activity, particularly against ovarian carcinoma, when anchored to AvidinOX, which allows enhanced and targeted fixation of the therapeutic agent within tumor tissues. The compound leverages the cytotoxic mechanism of camptothecin analogs, targeting DNA topoisomerase I to induce DNA damage and inhibit tumor cell growth. The combination with AvidinOX aims to improve local retention and efficacy of the chemotherapeutic[5][7].

Other names: biotinylated gimatecan-derived camptothecin

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on ST8161AA1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST8161AA1.

Explore the full profile